What is the role of CCR3 in choroidal neovascularization?

Yiwen Li, Deqiang Huang, Xin Xia, Zhengying Wang, Lingyu Luo, Rong Wen

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF) in CNV development has been clearly demonstrated and clinically VEGF neutralization has become standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and CCR3 targeting was believed to be superior to VEGF targeting for CNV suppression. Our data in the present work show that blocking CCR3 by a small molecule CCR3 antagonist SB 328437 or CCR3-neutralizing antibodies does not inhibit CNV in the Matrigel CNV models of rat and mouse, whereas VEGF-neutralizing antibodies or rapamycin effectively suppresses CNV. These results question the role of CCR3 in CNV development and the therapeutic approach to suppress CNV by CCR3 targeting.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
Pages279-284
Number of pages6
Volume723
DOIs
StatePublished - Jan 23 2012

Publication series

NameAdvances in Experimental Medicine and Biology
Volume723
ISSN (Print)00652598

Fingerprint

Choroidal Neovascularization
Vascular Endothelial Growth Factor A
Macular Degeneration
Neutralizing Antibodies
Sirolimus
Blindness
Developed Countries
Rats
Molecules
Therapeutics

Keywords

  • AMD
  • Angiogenesis
  • CCR3
  • CNV
  • Matrigel
  • Rapamycin
  • SB328437
  • VEGF-A

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Li, Y., Huang, D., Xia, X., Wang, Z., Luo, L., & Wen, R. (2012). What is the role of CCR3 in choroidal neovascularization? In Advances in Experimental Medicine and Biology (Vol. 723, pp. 279-284). (Advances in Experimental Medicine and Biology; Vol. 723). https://doi.org/10.1007/978-1-4614-0631-0_36

What is the role of CCR3 in choroidal neovascularization? / Li, Yiwen; Huang, Deqiang; Xia, Xin; Wang, Zhengying; Luo, Lingyu; Wen, Rong.

Advances in Experimental Medicine and Biology. Vol. 723 2012. p. 279-284 (Advances in Experimental Medicine and Biology; Vol. 723).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Li, Y, Huang, D, Xia, X, Wang, Z, Luo, L & Wen, R 2012, What is the role of CCR3 in choroidal neovascularization? in Advances in Experimental Medicine and Biology. vol. 723, Advances in Experimental Medicine and Biology, vol. 723, pp. 279-284. https://doi.org/10.1007/978-1-4614-0631-0_36
Li Y, Huang D, Xia X, Wang Z, Luo L, Wen R. What is the role of CCR3 in choroidal neovascularization? In Advances in Experimental Medicine and Biology. Vol. 723. 2012. p. 279-284. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-0631-0_36
Li, Yiwen ; Huang, Deqiang ; Xia, Xin ; Wang, Zhengying ; Luo, Lingyu ; Wen, Rong. / What is the role of CCR3 in choroidal neovascularization?. Advances in Experimental Medicine and Biology. Vol. 723 2012. pp. 279-284 (Advances in Experimental Medicine and Biology).
@inproceedings{eb3b8376f5b8470fbb24fb21ba351b5d,
title = "What is the role of CCR3 in choroidal neovascularization?",
abstract = "Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The {"}wet{"} AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF) in CNV development has been clearly demonstrated and clinically VEGF neutralization has become standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and CCR3 targeting was believed to be superior to VEGF targeting for CNV suppression. Our data in the present work show that blocking CCR3 by a small molecule CCR3 antagonist SB 328437 or CCR3-neutralizing antibodies does not inhibit CNV in the Matrigel CNV models of rat and mouse, whereas VEGF-neutralizing antibodies or rapamycin effectively suppresses CNV. These results question the role of CCR3 in CNV development and the therapeutic approach to suppress CNV by CCR3 targeting.",
keywords = "AMD, Angiogenesis, CCR3, CNV, Matrigel, Rapamycin, SB328437, VEGF-A",
author = "Yiwen Li and Deqiang Huang and Xin Xia and Zhengying Wang and Lingyu Luo and Rong Wen",
year = "2012",
month = "1",
day = "23",
doi = "10.1007/978-1-4614-0631-0_36",
language = "English",
isbn = "9781461406303",
volume = "723",
series = "Advances in Experimental Medicine and Biology",
pages = "279--284",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - GEN

T1 - What is the role of CCR3 in choroidal neovascularization?

AU - Li, Yiwen

AU - Huang, Deqiang

AU - Xia, Xin

AU - Wang, Zhengying

AU - Luo, Lingyu

AU - Wen, Rong

PY - 2012/1/23

Y1 - 2012/1/23

N2 - Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF) in CNV development has been clearly demonstrated and clinically VEGF neutralization has become standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and CCR3 targeting was believed to be superior to VEGF targeting for CNV suppression. Our data in the present work show that blocking CCR3 by a small molecule CCR3 antagonist SB 328437 or CCR3-neutralizing antibodies does not inhibit CNV in the Matrigel CNV models of rat and mouse, whereas VEGF-neutralizing antibodies or rapamycin effectively suppresses CNV. These results question the role of CCR3 in CNV development and the therapeutic approach to suppress CNV by CCR3 targeting.

AB - Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF) in CNV development has been clearly demonstrated and clinically VEGF neutralization has become standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and CCR3 targeting was believed to be superior to VEGF targeting for CNV suppression. Our data in the present work show that blocking CCR3 by a small molecule CCR3 antagonist SB 328437 or CCR3-neutralizing antibodies does not inhibit CNV in the Matrigel CNV models of rat and mouse, whereas VEGF-neutralizing antibodies or rapamycin effectively suppresses CNV. These results question the role of CCR3 in CNV development and the therapeutic approach to suppress CNV by CCR3 targeting.

KW - AMD

KW - Angiogenesis

KW - CCR3

KW - CNV

KW - Matrigel

KW - Rapamycin

KW - SB328437

KW - VEGF-A

UR - http://www.scopus.com/inward/record.url?scp=84862923678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862923678&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-0631-0_36

DO - 10.1007/978-1-4614-0631-0_36

M3 - Conference contribution

C2 - 22183343

AN - SCOPUS:84862923678

SN - 9781461406303

VL - 723

T3 - Advances in Experimental Medicine and Biology

SP - 279

EP - 284

BT - Advances in Experimental Medicine and Biology

ER -